Literature DB >> 9057563

Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group.

T Ozaki1, A Hillmann, C Hoffmann, C Rübe, B Dockhorn-Dworniczak, S Blasius, J Dunst, J Treuner, H Jürgens, W Winkelmann.   

Abstract

We reviewed the treatment outcome of 69 patients with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36%, 65%, and 65% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.

Entities:  

Mesh:

Year:  1997        PMID: 9057563     DOI: 10.3109/17453679709003970

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  2 in total

1.  Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience from a single institution.

Authors:  Gaetano Bacci; Stefano Boriani; Alba Balladelli; Enza Barbieri; Alessandra Longhi; Marco Alberghini; Katia Scotlandi; Cristiana Forni; Paola Pollastri; Daniel Vanel; Mario Mercuri
Journal:  Eur Spine J       Date:  2009-03-11       Impact factor: 3.134

2.  Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group.

Authors:  Najat C Daw; Nadia N Laack; Elizabeth J McIlvaine; Mark Krailo; Richard B Womer; Linda Granowetter; Holcombe E Grier; Neyssa M Marina; Mark L Bernstein; Mark C Gebhardt; Karen J Marcus; Shailesh M Advani; John H Healey; George D Letson; Richard G Gorlick; R Lor Randall
Journal:  Ann Surg Oncol       Date:  2016-05-23       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.